243 related articles for article (PubMed ID: 23951600)
1. Hepatitis C and interferon: fewer cases of liver cancer.
Prescrire Int; 2013 Jul; 22(140):191. PubMed ID: 23951600
[TBL] [Abstract][Full Text] [Related]
2. [Antiviral treatment reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related chronic hepatitis and cirrhosis].
Kasahara A; Hiramatsu N
Nihon Rinsho; 2011 May; 69 Suppl 4():314-8. PubMed ID: 22096937
[No Abstract] [Full Text] [Related]
3. [Effects of IFN therapy on incidence of hepatocellular carcinoma in HCV positive cirrhosis].
Nishiguchi S; Kubo S; Shiomi S
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):600-4. PubMed ID: 15359868
[No Abstract] [Full Text] [Related]
4. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
[TBL] [Abstract][Full Text] [Related]
5. Interferon therapy reduces the risk for hepatocellular carcinoma.
Brown JL
Gut; 2000 Nov; 47(5):610-1. PubMed ID: 11034573
[No Abstract] [Full Text] [Related]
6. Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis.
Masuzaki R; Yoshida H; Omata M
Oncology; 2010 Jul; 78 Suppl 1():17-23. PubMed ID: 20616579
[TBL] [Abstract][Full Text] [Related]
7. [Chronic hepatitis C: what to do if the first treatment failed?].
Asselah T
Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B50-9. PubMed ID: 12180309
[No Abstract] [Full Text] [Related]
8. [Treatment of hepatitis C virus-related cirrhosis].
Bronowicki JP
Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B220-4. PubMed ID: 12180292
[No Abstract] [Full Text] [Related]
9. [Multicenter study on the inhibition of hepatocarcinogenesis by interferon therapy (IHIT)].
Yoshida H; Omata M
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):463-6. PubMed ID: 15359842
[No Abstract] [Full Text] [Related]
10. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C.
Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):122-8. PubMed ID: 16706823
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome after interferon therapy in patients with chronic hepatitis C.
Buti M; Esteban R
Ann Hepatol; 2007; 6(4):267-9. PubMed ID: 18007558
[No Abstract] [Full Text] [Related]
12. Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon.
Veldt BJ; Hansen BE; Ikeda K; Verhey E; Suzuki H; Schalm SW
Scand J Gastroenterol; 2006 Sep; 41(9):1087-94. PubMed ID: 16938723
[TBL] [Abstract][Full Text] [Related]
13. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.
Imai Y; Tamura S; Tanaka H; Hiramatsu N; Kiso S; Doi Y; Inada M; Nagase T; Kitada T; Imanaka K; Fukuda K; Takehara T; Kasahara A; Hayashi N
J Viral Hepat; 2010 Mar; 17(3):185-91. PubMed ID: 19709362
[TBL] [Abstract][Full Text] [Related]
14. [Cost-effectiveness of antiviral therapy for chronic hepatitis C patients in prevention of hepatocellular cancer ].
Yoshida H; Tateishi R; Omata M
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):511-4. PubMed ID: 15359852
[No Abstract] [Full Text] [Related]
15. Antiviral treatment for cirrhosis due to hepatitis C: a review.
Somasundaram A; Venkataraman J
Singapore Med J; 2012 Apr; 53(4):231-5. PubMed ID: 22511042
[TBL] [Abstract][Full Text] [Related]
16. Resected cases of hepatocellular carcinoma detected after interferon therapy for chronic hepatitis C.
Kubo S; Nishiguchi S; Tamori A; Hirohashi K; Tanaka H; Tsukamoto T; Shuto T; Kuroki T; Kinoshita H
Hepatogastroenterology; 2000; 47(34):1100-2. PubMed ID: 11020887
[TBL] [Abstract][Full Text] [Related]
17. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
[TBL] [Abstract][Full Text] [Related]
18. [Hepatitis C and alcohol].
Perlemuter G
Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B105-11. PubMed ID: 12180277
[No Abstract] [Full Text] [Related]
19. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.
Yoshida H; Shiratori Y; Moriyama M; Arakawa Y; Ide T; Sata M; Inoue O; Yano M; Tanaka M; Fujiyama S; Nishiguchi S; Kuroki T; Imazeki F; Yokosuka O; Kinoyama S; Yamada G; Omata M
Ann Intern Med; 1999 Aug; 131(3):174-81. PubMed ID: 10428733
[TBL] [Abstract][Full Text] [Related]
20. [Histological findings in the liver in patients with chronic hepatitis C].
Takase K; Shiraki K
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):434-8. PubMed ID: 15359838
[No Abstract] [Full Text] [Related]
[Next] [New Search]
